CHF95.42
0.16% today
SIX Swiss Exchange, Jun 18, 11:13 am CET
ISIN
CH0012005267
Symbol
NOVN
Sector
Industry

Novartis Stock price

CHF95.57
+4.02 4.39% 1M
+6.85 7.72% 6M
+6.87 7.75% YTD
+2.03 2.17% 1Y
+15.93 20.00% 5Y
+18.14 23.42% 10Y
+45.19 89.70% 20Y
SIX Swiss Exchange, Closing price Tue, Jun 17 2025
-0.80 0.83%
ISIN
CH0012005267
Symbol
NOVN
Sector
Industry

Key metrics

Market capitalization CHF183.41b
Enterprise Value CHF203.04b
P/E (TTM) P/E ratio 18.03
EV/FCF (TTM) EV/FCF 16.75
EV/Sales (TTM) EV/Sales 4.67
P/S ratio (TTM) P/S ratio 4.22
P/B ratio (TTM) P/B ratio 5.98
Dividend yield 3.66%
Last dividend (FY24) CHF3.50
Revenue growth (TTM) Revenue growth 11.57%
Revenue (TTM) Revenue CHF43.48b
EBIT (operating result TTM) EBIT CHF14.23b
Free Cash Flow (TTM) Free Cash Flow CHF12.12b
Cash position CHF5.83b
EPS (TTM) EPS CHF5.30
P/E forward 17.07
P/S forward 4.16
EV/Sales forward 4.61
Show more

Create a Free Account to create an Novartis alert.

Set up alerts on Stock Price, Dividend Yield, Valuation (e.g. P/E or EV/Sales) or Strategy Scores and sit back and relax.

Novartis Stock Analysis

Unlock Scores for Free

Analyst Opinions

24 Analysts have issued a Novartis forecast:

5x Buy
21%
13x Hold
54%
6x Sell
25%

Analyst Opinions

24 Analysts have issued a Novartis forecast:

Buy
21%
Hold
54%
Sell
25%

Financial data from Novartis

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
43,478 43,478
12% 12%
100%
- Direct Costs 10,571 10,571
3% 3%
24%
32,908 32,908
15% 15%
76%
- Selling and Administrative Expenses 10,434 10,434
3% 3%
24%
- Research and Development Expense 7,675 7,675
12% 12%
18%
14,427 14,427
55% 55%
33%
- Depreciation and Amortization 198 198
212% 212%
0%
EBIT (Operating Income) EBIT 14,229 14,229
54% 54%
33%
Net Profit 10,498 10,498
16% 16%
24%

In millions CHF.

Don't miss a Thing! We will send you all news about Novartis directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Novartis Stock News

AD HOC NEWS
16 days ago
Novartis CH0012005267 hat positive Zwischenergebnisse einer Studie mit seiner Krebstherapie Pluvicto veröffentlicht.
AD HOC NEWS
17 days ago
Der schweizerische Pharmakonzern Novartis CH0012005267 hat beim diesjährigen Krebs-Kongress ASCO in Chicago weitere Daten zu seinem Brustkrebsmittel Kisqali vorgestellt.
marktEINBLICKE
about one month ago
Der Schweizer Pharmakonzern hatte trotz des US-Gegenwinds zuletzt häufiger gute Nachrichten parat - zur Freude der Aktionäre.
More Novartis News

Company Profile

Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment researches, develops, manufactures, distributes and sells patented pharmaceuticals, and is composed of two business units: Novartis Oncology and Novartis Pharmaceuticals. The Sandoz segment develops, manufactures and markets finished dosage form medicines as well as intermediary products including active pharmaceutical ingredients. The Corporate segment refers to group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Head office Switzerland
CEO Vasant Narasimhan
Employees 76,057
Founded 1996
Website www.novartis.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today